{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:41:16Z","timestamp":1791517276903,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtho.2026.103649","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:21:33Z","timestamp":1773836493000},"page":"103649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor Inflammation\u2013Associated Neurotoxicity Masquerading as Severe Immune Effector Cell\u2013Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-0875","authenticated-orcid":false,"given":"Masahiro","family":"Torasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehito","family":"Shukuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reitaro","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Ayame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsutaro","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103649_bib1","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103649_bib2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103649_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtho.2026.103649_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2026.103649_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.103649_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41582-025-01112-8","article-title":"Neurological complications of CAR T cell therapy for cancers","volume":"21","author":"Karschnia","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jtho.2026.103649_bib7","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood.2025028964","article-title":"Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy","volume":"146","author":"Kaulen","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2026.103649_bib8","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/epi.18338","article-title":"Updated classification of epileptic seizures: position paper of the International League Against Epilepsy","volume":"66","author":"Beniczky","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.jtho.2026.103649_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jtho.2025.02.023","article-title":"Rapid intracranial response with tarlatamab in patients with untreated brain metastases from SCLC-A real-world case series: case report","volume":"20","author":"Zhang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103649_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103649_bib11","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200111","article-title":"Frontal intermittent rhythmic delta activity is a useful diagnostic tool of neurotoxicity after CAR T-cell infusion","volume":"10","author":"Huby","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jtho.2026.103649_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/neuonc\/noab174","article-title":"EEG findings in CAR T-cell-associated neurotoxicity: clinical and radiological correlations","volume":"24","author":"Beuchat","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtho.2026.103649_bib13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/bloodadvances.2023011896","article-title":"Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma","volume":"8","author":"Nie","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtho.2026.103649_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108730","article-title":"Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer","volume":"207","author":"Shijubou","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103649_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.70319","article-title":"Early pseudoprogression after tarlatamab in small-cell lung cancer: a case report","volume":"13","author":"Nakano","year":"2025","journal-title":"Respirol Case Rep"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:41:03Z","timestamp":1783071663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1556086426001024"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103649","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Inflammation\u2013Associated Neurotoxicity Masquerading as Severe Immune Effector Cell\u2013Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103649"}}